title: Substitution of valine-865 by methionine or leucine in the human androgen receptor causes complete or partial androgen insensitivity, respectively with distinct androgen receptor phenotypes.
abstract: We have identified two different single nucleotide missense substitutions at valine-865 in exon 7 of the human androgen receptor (AR) gene in two families with androgen resistance. Val-->methionine is associated with the complete syndrome; Val-->leucine is associated with the partial form. In genital skin fibroblasts, both alterations yield a normal maximum binding capacity, but an increased apparent equilibrium dissociation constant for all androgens tested. In genital skin fibroblasts, Val865-Met A-R complexes have increased rate constants of dissociation with 5 alpha-dihydrotestosterone, and the nonmetabolized ligands methyltrienolone or mibolerone (MB); their Val865-Leu counterparts have increased rates with methyltrienolone and MB, but not with 5 alpha-dihydrotestosterone. In transiently transfected COS-1 or PC-3 cells, Met865 AR is more severely impaired than Leu865 AR in transactivating two different androgen-responsive reporter constructs, thereby correlating with clinical phenotype. In COS-1 cells exposed to MB for 74 h, this relative impairment correlates with the relative instability of the MB-binding activity of each mutant AR, suggesting that their respective intrinsic transcriptional regulatory competence is normal. Notably, these mutant ARs lose significantly more MB-binding activity than immunoreactivity, suggesting that prolonged MB exposure induces them to adopt a nonbinding state. The position homologous to Val865 in the AR is occupied by Leu or Met in the three steroid receptors closely related to the AR. This indicates the structural subtlety that underlies the steroid-binding activity of different steroid receptors.
authors.affiliation: Lady Davis Institute for Medical Research Department of Biology, McGill University Montreal, Quebec, Canada.
authors.forename: P
authors.initials: P
authors.lastname: Kazemi-Esfarjani
authors.forename: L K
authors.initials: LK
authors.lastname: Beitel
authors.forename: M
authors.initials: M
authors.lastname: Trifiro
authors.forename: M
authors.initials: M
authors.lastname: Kaufman
authors.forename: P
authors.initials: P
authors.lastname: Rennie
authors.forename: P
authors.initials: P
authors.lastname: Sheppard
authors.forename: R
authors.initials: R
authors.lastname: Matusik
authors.forename: L
authors.initials: L
authors.lastname: Pinsky
mesh_terms: D000595:Amino Acid Sequence; D013734:Androgen-Insensitivity Syndrome / Q000235:genetics*; D000818:Animals; D001483:Base Sequence; D002478:Cells, Cultured; D002522:Chlorocebus aethiops; D013196:Dihydrotestosterone / Q000378:metabolism; D005091:Exons; D005347:Fibroblasts / Q000378:metabolism; D005796:Genes; D005837:Genitalia, Male; D006801:Humans; D008297:Male; D008969:Molecular Sequence Data; D009154:Mutation; D009277:Nandrolone / Q000031:analogs & derivatives / Q000378:metabolism; D010641:Phenotype; D016133:Polymerase Chain Reaction; D011944:Receptors, Androgen / Q000235:genetics*; D011987:Receptors, Steroid / Q000235:genetics; D011994:Recombinant Proteins / Q000378:metabolism; D017386:Sequence Homology, Amino Acid; D012867:Skin
chemical_list: D011944:Receptors, Androgen; D011987:Receptors, Steroid; D011994:Recombinant Proteins; D013196:Dihydrotestosterone; D009277:Nandrolone; C100075:mibolerone